Matthew E. Korenberg
Net Worth
Last updated:
What is Matthew E. Korenberg net worth?
The estimated net worth of Mr. Matthew E. Korenberg is at least $26,170,259 as of 23 Sep 2024. He owns shares worth $7,568,312 as insider, has earned $12,569,227 from insider trading and has received compensation worth at least $6,032,720 in Ligand Pharmaceuticals Incorporated.
What is the salary of Matthew E. Korenberg?
Mr. Matthew E. Korenberg salary is $754,090 per year as Executive Vice President of Fin. & Chief Financial Officer in Ligand Pharmaceuticals Incorporated.
How old is Matthew E. Korenberg?
Mr. Matthew E. Korenberg is 50 years old, born in 1975.
What stocks does Matthew E. Korenberg currently own?
As insider, Mr. Matthew E. Korenberg owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | Executive Vice President of Fin. & Chief Financial Officer | 50,777 | $149.05 | $7,568,312 |
What does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Matthew E. Korenberg insider trading
Ligand Pharmaceuticals Incorporated
Mr. Matthew E. Korenberg has made 15 insider trades between 2017-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 18,357 units of LGND stock on 29 Aug 2018. As of 23 Sep 2024 he still owns at least 50,777 units of LGND stock.
Ligand Pharmaceuticals Incorporated key executives
Ligand Pharmaceuticals Incorporated executives and other stock owners filed with the SEC:
- Mr. Charles S. Berkman (56) Senior Vice President, Gen. Counsel & Sec.
- Mr. John L. Higgins (55) Chief Executive Officer & Executive Director
- Mr. Matthew E. Korenberg (50) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Matthew W. Foehr (52) Pres & Chief Operating Officer